|Bid||13.95 x 3000|
|Ask||14.11 x 2900|
|Day's range||13.97 - 14.10|
|52-week range||13.91 - 19.97|
|Beta (5Y monthly)||1.10|
|PE ratio (TTM)||11.76|
|Forward dividend & yield||0.84 (5.97%)|
|Ex-dividend date||30 Mar 2021|
|1y target est||N/A|
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
The prescription drugmaker is halting a trial before a scheduled stopping point, suggesting it's too dangerous to expect an approval.
(Bloomberg) -- Takeda Pharmaceutical Co., a drugmaker that distributes Moderna Inc.’s vaccine in Japan, is planning what would be its second-biggest yen bond sale ever next week.The Tokyo-based company is scheduled to price a 200 billion yen ($1.8 billion) 10-year note on Oct. 8, and intends to use the funds to refinance its existing debt, according to underwriter SMBC Nikko Securities Inc. That would be its largest Japanese-currency sale after a jumbo 500 billion yen offering in 2019 to help pa